Meropenem

Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs

Retrieved on: 
Monday, March 14, 2022
Health, FDA, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Associate, Infection, HIV, Disease, Metabolism, Minocycline, Albany Medical College, GlaxoSmithKline, Meropenem, Director, LLC, Injection, Medical Affairs Bureau, Virology, CNS, Health, Board, Merck, Leadership, Executive Committee, Boehringer Ingelheim, Patient, Therapy, Organization, Medical device, Management, Pharmaceutical industry, Medicine, Mallinckrodt, Immunology, Melinta Therapeutics

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today.

Key Points: 
  • Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today.
  • Dr. Piliero, an Infectious Disease specialist and global Medical Affairs leader, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller.
  • Additionally, Dr. Piliero will help Melinta continue to stand out as a thought leader in the important conversations happening in scientific and medical communities today.
  • Dr. Piliero joins Melinta from GSK Consumer Healthcare, where he led Medical Affairs Americas.

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio

Retrieved on: 
Thursday, January 6, 2022
Health, Other Science, Pharmaceutical, Science, Optical, Biotechnology, Chemical engineering, ISEE, Therapy, Minocycline, Injection, Acquisition, Geographic atrophy, Growth, Stevens Institute of Technology, Company, Patient, Allergan, Vance DeGeneres, Merck, LLC, Board, Business administration, Master of Business Administration, Rensselaer Polytechnic Institute, Board of directors, Nasdaq, Multimedia, Retina, Meropenem, Leadership, Management, Pharmaceutical industry, Fine chemical, Actavis, Novartis, Technology, Melinta Therapeutics, Novartis

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that President and Chief Executive Officer Christine Ann Miller has been elected to the Board of Directors of IVERIC bio, Inc. (Nasdaq: ISEE), effective immediately.

Key Points: 
  • Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that President and Chief Executive Officer Christine Ann Miller has been elected to the Board of Directors of IVERIC bio, Inc. (Nasdaq: ISEE), effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20220105006048/en/
    Melinta Therapeutics President and Chief Executive Officer Christine Ann Miller (Photo: Business Wire)
    Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • I am thrilled to join the impressive Iveric Bio board and to have the opportunity to work with a highly dedicated executive team at this pivotal time, said Ms. Miller.
  • Iveric Bio Chief Executive Officer Glenn P. Sblendorio said, We are excited to welcome Christine, a highly qualified executive in the life-science industry, to our Board of Directors.

Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

Retrieved on: 
Monday, October 25, 2021
Infectious Diseases, Cardiology, Stem Cells, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Drug development, Nephrology, Cardiology, Meropenem, Wyeth, Pfizer, Patient, Staphylococcus aureus, Minocycline, Boehringer Ingelheim, Degenerative disease, LLC, Growth, Therapy, Injection, Ophthalmology, Medical device, Pharmaceutical industry

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.

Key Points: 
  • Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.
  • Dr. Girgenti, a global leader in clinical research and drug development, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller.
  • With the addition of Dr. Girgenti, Melinta expects to expand its world-class portfolio while continuing to drive operational excellence.
  • Dr. Girgenti joins Melinta from Magenta Therapeutics where he led clinical development programs for stem-cell mobilization and autoimmune diseases.

Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

Retrieved on: 
Monday, September 20, 2021
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, ACT, Therapy, OPPS, Meropenem, Clostridioides, Partial thromboplastin time, Program, MRSA, Minocycline, Staphylococcus aureus, Back pain, Bleeding, Injection, Streptococcus agalactiae, Gram, Genetically modified bacteria, PT, Diarrhea, Center for Medicare and Medicaid Innovation, Food, Regulation of tobacco by the U.S. Food and Drug Administration, MSSA, Methicillin-resistant Staphylococcus aureus, Medicare, Centers for Medicare & Medicaid Services, Adult, Itch, Streptococcus anginosus group, Drug of last resort, Glycopeptide, Elective surgery, Headache, Vomiting, Enterococcus faecalis, Patient, CMS, Limb, Nausea, INR, Warfarin, Risk, Tremor, Streptococcus pyogenes, Chest pain, ASC, Infection, Anaphylaxis, Hypersensitivity, Osteomyelitis, Prospective payment system, Center, Heparin, Chills, Pharmaceutical industry, Hospital, Sales, Vaccine

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.

Key Points: 
  • Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.
  • We are thrilled to announce these two milestones that will expand reimbursement and access for KIMYRSA, said Christine Ann Miller, Melintas President and Chief Executive Officer.
  • Thats why we intentionally designed KIMYRSA to provide patients with more flexibility and accessibility in ABSSSI treatment.
  • Said John Harlow, Chief Commercial Officer for Melinta, Having a unique J-code for KIMYRSA underscores the distinct value that KIMYRSA brings to the oritavancin franchise.

DGAP-News: PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS

Retrieved on: 
Wednesday, September 1, 2021
Sepsis, Philippe Ciais, Hypotension, Royal commission, Abscess, Anesthesia, Angiotensin, Peritonitis, Product, Meropenem, AG, Infectious Diseases Society of America, Intra-abdominal infection, Abdominal cavity, IDSA, Carbapenem, Infection, European Medicines Agency, Ertapenem, Aachen, Remimazolam, EU, ICU, PA8, Shock, ISIN, Catecholamine, Patient, Septic, European Commission, Multiplicity of infection, Tetracycline, Critical care, Frankfurt Stock Exchange, Health, Antibiotics, Pharmaceutical industry, complicated intra-abdominal infections (cIAI), XERAVA(R) (eravacycline), PAION, COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), XERAVA(R) (ERAVACYCLINE), PAION

XERAVA(R) is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.

Key Points: 
  • XERAVA(R) is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
  • XERAVA(R) is a fluorocycline antibiotic within the tetracycline class of antibacterial drugs and provides broad-spectrum coverage against different bacterial pathogens responsible for complicated intra-abdominal infections (cIAI).
  • Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "XERAVA is an important new treatment option for patients suffering from serious intra-abdominal infections.
  • XERAVA(R) is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

Investigation Report on China's Meropenem Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, Pharmaceutical, Countries, Health, Articles, Sumitomo Group, Meropenem, Pyrrolidines, Sumitomo Dainippon Pharma, Imperial Chemical Industries, COVID-19 pandemic, China

b'The "Investigation Report on China\'s Meropenem Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019.

Key Points: 
  • b'The "Investigation Report on China\'s Meropenem Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019.
  • In 2020, sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year.
  • The main reason is that the COVID-19 epidemic has impacted the hospitals\' overall operation.
  • Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial Chemical Industries (ICI).

Shionogi Announces FDA Approval of FETROJA® (cefiderocol) for the Treatment of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia

Retrieved on: 
Monday, September 28, 2020
Biotechnology, FDA, Pharmaceutical, Health, Medical specialties, RTT, Health, Medicine, Pyrrolidines, Carbapenem antibiotics, Infectious diseases, Meropenem, Shionogi, Urinary tract infection, Cefiderocol, Pyelonephritis, APEKS-NP, FETROJA® (cefiderocol) for injection, Shionogi

FETROJA is currently approved for patients 18 years of age or older for the treatment of complicated urinary tract infections, including pyelonephritis, caused by Gram-negative pathogens.

Key Points: 
  • FETROJA is currently approved for patients 18 years of age or older for the treatment of complicated urinary tract infections, including pyelonephritis, caused by Gram-negative pathogens.
  • Safety was investigated up to 28 days after the end of treatment unless there was an ongoing adverse event(s) which were followed up until their resolution.
  • The study found that FETROJA:
    Met the primary endpoint of non-inferiority to high-dose meropenem, infused over three hours.
  • Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in N.J. For more information on Shionogi Inc., please visit www.shionogi.com .

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

Retrieved on: 
Wednesday, May 6, 2020
Drugs, Health, Medicine, Carbapenem antibiotics, Moraxellaceae, Bacterial diseases, Gram-negative bacteria, Meropenem, RTT, Acinetobacter baumannii, β-Lactamase inhibitor, Beta-lactamase

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.

Key Points: 
  • ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.
  • This is Antabio's second program to receive QIDP status, following QIDP designation of its Metallo Beta-Lactamase Inhibitor ANT2681 for cUTI awarded in June 2019.
  • Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need.
  • Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development:
    SBLi Program.

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

Retrieved on: 
Wednesday, May 6, 2020
Drugs, Health, Medicine, Carbapenem antibiotics, Moraxellaceae, Bacterial diseases, Gram-negative bacteria, Meropenem, RTT, Acinetobacter baumannii, β-Lactamase inhibitor, Beta-lactamase

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.

Key Points: 
  • ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.
  • This is Antabio's second program to receive QIDP status, following QIDP designation of its Metallo Beta-Lactamase Inhibitor ANT2681 for cUTI awarded in June 2019.
  • Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need.
  • Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development:
    SBLi Program.

Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model

Retrieved on: 
Monday, May 4, 2020
Carbapenem antibiotics, Drugs, Organic compounds, Pyrrolidines, Chemistry, Carbapenem, Antibiotic, Recce, Meropenem, Draft:Recce Pharmaceuticals Ltd

In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model.

Key Points: 
  • In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model.
  • The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.
  • Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.